Antibe Therapeutics Inc (ATE.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
(Values in thousands)
| 03-2013 | 03-2012 | |
| Cash Flows From Operating Activities | ||
| Accounts receivable | -131 | 0 |
| Other Working Capital | 413 | 717 |
| Other Operating Activity | -763 | -942 |
| Operating Cash Flow | $-481 | $-225 |
| Cash Flows From Investing Activities | ||
| Investing Cash Flow | $N/A | $N/A |
| Cash Flows From Financing Activities | ||
| Debt Issued | 790 | 0 |
| Common Stock Issued | 85 | 411 |
| Other Financing Activity | -293 | -97 |
| Financing Cash Flow | $582 | $315 |
| Beginning Cash Position | 93 | 4 |
| End Cash Position | 194 | 93 |
| Net Cash Flow | $101 | $89 |
| Free Cash Flow | ||
| Operating Cash Flow | -481 | -225 |
| Free Cash Flow | -481 | -225 |